Black Diamond Therapeutics (BDTX) Earnings Analysis

Black Diamond Therapeutics (BDTX) next reports earnings on 2026-08-06, consensus EPS -0.18 USD. Last quarter (2026-05-07) it beat with EPS -0.16 USD vs -0.18 USD est (+11.1%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -2.41.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BDTX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.18 USD
Revenue estimaten/a

BDTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.16 USD-0.18 USD+11.1%Beat
2026-03-16-0.14 USD-0.18 USD+22.2%Beat
2025-11-06-0.15 USD-0.22 USD+31.8%Beat
2025-05-120.98 USD0.02 USD+4800%Beat
2025-03-06-0.28 USD-0.31 USD+9.7%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

BDTX valuation and analyst view

Trailing P/E-2.41
Trailing EPS-0.755 USD
Price / book1.00
Dividend yield0.00%
Market cap0.10B
Analyst consensusBuy (10 buy / 1 hold / 0 sell)
Avg price target8 USD

Related research pages

Frequently asked questions

When is Black Diamond Therapeutics (BDTX)'s next earnings date?

Black Diamond Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.18 USD.

Did BDTX beat earnings last quarter?

In its 2026-05-07 report, BDTX posted EPS of -0.16 USD versus a -0.18 USD estimate — a beat of 11.1%.

What is BDTX's earnings track record?

Over the last 5 reported quarters with consensus data, BDTX beat estimates 5 times (100%).

What is BDTX's current P/E ratio and EPS?

BDTX trades at a trailing P/E of -2.41 on trailing EPS of -0.754996037017747 USD.

What do analysts rate BDTX?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 8 USD.